XML 45 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Financial Information By Quarter (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2017
Quarterly Financial Information [Abstract]  
Schedule of quarterly financial information
Financial Information By Quarter (Unaudited)

 
Three Months Ended
2017
March 31
 
June 30
 
September 30
 
December 31
 
(in thousands, except for per share data)
Revenues
$
5,202

 
$
4,265

 
$
1,390

 
$
1,412

Selling, general and administrative
2,870

 
3,058

 
3,094

 
3,281

Research and development
6,360

 
5,068

 
2,471

 
2,781

Patent expenses
241

 
197

 
251

 
221

Lease termination
—

 
—

 
1,225

 
—

Operating loss
(4,269
)
 
(4,059
)
 
(5,651
)
 
(4,871
)
Net loss
(8,615
)
 
(7,501
)
 
(9,816
)
 
(10,303
)
Loss per common share: basic and diluted
$
(0.11
)
 
$
(0.10
)
 
$
(0.12
)
 
$
(0.13
)


 
Three Months Ended
2016
March 31
 
June 30
 
September 30
 
December 31
 
(in thousands, except for per share data)
Revenues
$
1,270

 
$
1,901

 
$
4,658

 
$
7,159

Selling, general and administrative
2,656

 
3,739

 
2,855

 
4,464

Research and development
2,536

 
2,948

 
6,069

 
8,158

Patent expenses
220

 
240

 
230

 
219

Interest on PharmAthene liability
2,917

 
4,259

 
3,566

 
927

Operating loss
(7,059
)
 
(9,285
)
 
(8,062
)
 
(6,609
)
Net loss
(10,449
)
 
(9,566
)
 
(9,244
)
 
(10,439
)
Loss per common share: basic and diluted
$
(0.19
)
 
$
(0.18
)
 
$
(0.17
)
 
$
(0.15
)